Literature DB >> 23257359

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Michael A Augello1, Craig J Burd, Ruth Birbe, Christopher McNair, Adam Ertel, Michael S Magee, Daniel E Frigo, Kari Wilder-Romans, Mark Shilkrut, Sumin Han, Danielle L Jernigan, Jeffry L Dean, Alessandro Fatatis, Donald P McDonnell, Tapio Visakorpi, Felix Y Feng, Karen E Knudsen.   

Abstract

Cyclin D1b is a splice variant of the cell cycle regulator cyclin D1 and is known to harbor divergent and highly oncogenic functions in human cancer. While cyclin D1b is induced during disease progression in many cancer types, the mechanisms underlying cyclin D1b function remain poorly understood. Herein, cell and human tumor xenograft models of prostate cancer were utilized to resolve the downstream pathways that are required for the protumorigenic functions of cyclin D1b. Specifically, cyclin D1b was found to modulate the expression of a large transcriptional network that cooperates with androgen receptor (AR) signaling to enhance tumor cell growth and invasive potential. Notably, cyclin D1b promoted AR-dependent activation of genes associated with metastatic phenotypes. Further exploration determined that transcriptional induction of SNAI2 (Slug) was essential for cyclin D1b-mediated proliferative and invasive properties, implicating Slug as a critical driver of disease progression. Importantly, cyclin D1b expression highly correlated with that of Slug in clinical samples of advanced disease. In vivo analyses provided strong evidence that Slug enhances both tumor growth and metastatic phenotypes. Collectively, these findings reveal the underpinning mechanisms behind the protumorigenic functions of cyclin D1b and demonstrate that the convergence of the cyclin D1b/AR and Slug pathways results in the activation of processes critical for the promotion of lethal tumor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257359      PMCID: PMC3533295          DOI: 10.1172/JCI64750

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  67 in total

1.  D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability.

Authors:  K E Knudsen; W K Cavenee; K C Arden
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

2.  Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism.

Authors:  F Bienvenu; H Gascan; O Coqueret
Journal:  J Biol Chem       Date:  2001-02-20       Impact factor: 5.157

3.  Quantitative analysis of chromosome conformation capture assays (3C-qPCR).

Authors:  Hélène Hagège; Petra Klous; Caroline Braem; Erik Splinter; Job Dekker; Guy Cathala; Wouter de Laat; Thierry Forné
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

4.  TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells.

Authors:  Vincenzo Cesi; Arianna Casciati; Fabiola Sesti; Barbara Tanno; Bruno Calabretta; Giuseppe Raschellà
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Mouse cDNA microarray analysis uncovers Slug targets in mouse embryonic fibroblasts.

Authors:  Camino Bermejo-Rodríguez; María Pérez-Caro; Pedro Antonio Pérez-Mancera; Margarita Sánchez-Beato; Miguel A Piris; Isidro Sánchez-García
Journal:  Genomics       Date:  2005-11-28       Impact factor: 5.736

7.  CCND1 G870A polymorphism is associated with increased risk of colorectal cancer, especially for sporadic colorectal cancer and in Caucasians: a meta-analysis.

Authors:  Jing Yang; Guoxin Zhang; Jianping Chen
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-02-07       Impact factor: 2.947

8.  Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.

Authors:  Chenguang Wang; Nagarajan Pattabiraman; Jian Nian Zhou; Maofu Fu; Toshiyuki Sakamaki; Chris Albanese; Zhiping Li; Kongming Wu; James Hulit; Peter Neumeister; Phyllis M Novikoff; Michael Brownlee; Philipp E Scherer; Joan G Jones; Kathleen D Whitney; Lawrence A Donehower; Emily L Harris; Thomas Rohan; David C Johns; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

9.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

10.  Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Authors:  David A Solomon; Ying Wang; Sejal R Fox; Tah C Lambeck; Sarah Giesting; Zhengdao Lan; Adrian M Senderowicz; Claudio J Conti; Erik S Knudsen
Journal:  J Biol Chem       Date:  2003-05-12       Impact factor: 5.157

View more
  25 in total

1.  Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Yi Liu; Christopher McNair; Alex Haber; Maryna Perepelyuk; Anshul Bhardwaj; Sankar Addya; Adam Ertel; Sunday Shoyele; Ruth Birbe; Joseph M Salvino; Adam P Dicker; Karen E Knudsen; Robert B Den
Journal:  Clin Cancer Res       Date:  2018-01-08       Impact factor: 12.531

2.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Authors:  Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

3.  RB Loss Promotes Prostate Cancer Metastasis.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Yi Liu; Alex Haber; Adam Ertel; Anshul Bhardwaj; Sankar Addya; Noelle Williams; Stephen J Ciment; Paolo Cotzia; Jeffry L Dean; Adam Snook; Chris McNair; Matt Price; James R Hernandez; Shuang G Zhao; Ruth Birbe; James B McCarthy; Eva A Turley; Kenneth J Pienta; Felix Y Feng; Adam P Dicker; Karen E Knudsen; Robert B Den
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

4.  Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression.

Authors:  Alicia M Blessing; Kimal Rajapakshe; Lakshmi Reddy Bollu; Yan Shi; Mark A White; Alexander H Pham; Chenchu Lin; Philip Jonsson; Constanza J Cortes; Edwin Cheung; Albert R La Spada; Robert C Bast; Fatima A Merchant; Cristian Coarfa; Daniel E Frigo
Journal:  Autophagy       Date:  2016-12-15       Impact factor: 16.016

Review 5.  Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.

Authors:  Jacqueline Olender; Norman H Lee
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 6.  AR function in promoting metastatic prostate cancer.

Authors:  Michael A Augello; Robert B Den; Karen E Knudsen
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

7.  The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.

Authors:  Ettickan Boopathi; Steve Ciment; Chellappagounder Thangavel; Yi Liu; Raymond O'Neill; Ankur Sharma; Steve B McMahon; Hestia Mellert; Sankar Addya; Adam Ertel; Ruth Birbe; Paolo Fortina; Adam P Dicker; Karen E Knudsen; Robert B Den
Journal:  Clin Cancer Res       Date:  2014-08-27       Impact factor: 12.531

8.  Improvement in Therapeutic Efficacy and Reduction in Cellular Toxicity: Introduction of a Novel Anti-PSMA-Conjugated Hybrid Antiandrogen Nanoparticle.

Authors:  Chellappagounder Thangavel; Maryna Perepelyuk; Ettickan Boopathi; Yi Liu; Steven Polischak; Deepak A Deshpande; Khadija Rafiq; Adam P Dicker; Karen E Knudsen; Sunday A Shoyele; Robert B Den
Journal:  Mol Pharm       Date:  2018-04-04       Impact factor: 4.939

Review 9.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

Review 10.  The double dealing of cyclin D1.

Authors:  Guergana Tchakarska; Brigitte Sola
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.